FDA approves Olaparib Plus Abiraterone and Prednisone or Prednisolone for BRCA-mutated metastatic castration-resistant prostate cancer

Be allowed

By the staff of ASCO Post Posted: 2/6/2023 12:43:00 Last update: 6/2/2023 12:38:22 On May 31, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in combination with abiraterone and prednisone (or prednisolone) for adult patients with suspected or deleterious disease BRCA extensionmutated metastatic castration-resistant prostate cancer, as determined by an accompanying FDA-approved diagnostic … Read more